Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology
SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties
The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products, including a number of generic products focused on women’s health.
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
An estimated 21 million American women experience BV
The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
Acute therapies continue to report strong growth compared to chronic ones.
Subscribe To Our Newsletter & Stay Updated
